Latest News & Features
Americas
It is certain that both inter partes and post-grant reviews will continue to shape the landscape for biologics patents and biosimilars, says Jennifer Fox of Brinks Gilson & Lione. 1 June 2018
Americas
Product development partnerships are likely to provide great opportunities for companies seeking to market biosimilar products in Brazil, where there is a huge reliance on public healthcare. Alice Rayol Sandes of Di Blasi, Parente & Associados has more. 1 June 2018
Americas
Brazil’s patent backlog has long caused concern for IP owners, particularly those in the pharmaceutical industry, but progress is being made, as Kene Gallois and Ricardo Nunes of Daniel Legal & IP Strategy report. 31 May 2018
Americas
Artificial intelligence is being used increasingly in the pharma and biotech industries, and questions are being asked about the legal status of innovations created by the technology, as MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch reports. 31 May 2018
Asia
In India, there are two core areas of the antibody patenting field that are unsettled and need correcting, as Archana Shanker and Nupur Maithani of Anand and Anand explain. 31 May 2018
Americas
Research and development, strong IP rights and good international relations are all factors in Brazil’s rise as a soybean-producing powerhouse, as Gabriel Di Blasi and Matheus Gil do Amaral of Di Blasi Parente & Associados report. 29 May 2018
Asia
The Indian Patent Office has attempted to bridge the divide between the laws on patents and biological diversity, but instead it created a maze of problems, says Vidisha Garg of Anand and Anand. 15 May 2018
Africa
There may be a path through the CRISPR patent jungle, but there are many obstacles still in the way, say European academics Timo Minssen, Esther van Zimmeren and Jakob Wested. 8 May 2018
Americas
Courts have not always been able to appreciate the complexities around antibody patents, causing problems for innovation and investment, says Eli Lilly patent counsel Duane Marks in an interview with LSIPR. 17 April 2018
article
Variable sequence IP is fertile ground for potential validity challenges based on prior art or lack of enablement, as Ellen Sherin of GQ Life Sciences reports. 12 April 2018